Burney Co. Sells 2,766 Shares of McKesson Corporation $MCK

Key Points

• Burney Co. reduced its McKesson stake by 4.7% in Q4, selling 2,766 shares and leaving 56,356 shares worth $46.23 million, which represents about 1.4% of Burney's holdings and is its 12th-largest position.
• McKesson beat quarterly expectations, reporting $9.34 EPS vs. $9.19 expected and $106.16 billion in revenue (up 11.4% YoY), and set FY2026 guidance of $38.80–$39.20 EPS versus sell-side consensus of roughly $32.77.
• Insiders have been sellers (3,592 shares sold, ~$3.52M in the past three months), the company pays a $0.82 quarterly dividend (annualized $3.28, ~0.4% yield), and analysts rate McKesson a "Moderate Buy" with a consensus target near $970.93.

Burney Co. cut its position in McKesson Corporation (NYSE:MCK - Free Report) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 56,356 shares of the company's stock after selling 2,766 shares during the quarter. McKesson accounts for about 1.4% of Burney Co.'s holdings, making the stock its 12th biggest holding. Burney Co.'s holdings in McKesson were worth $46,228,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. GGM Financials LLC bought a new position in McKesson in the third quarter valued at about $25,000. State of Wyoming bought a new position in shares of McKesson during the second quarter worth about $29,000. Hopwood Financial Services Inc. bought a new position in shares of McKesson during the third quarter worth about $31,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of McKesson during the third quarter worth about $33,000. Finally, Board of the Pension Protection Fund bought a new position in shares of McKesson during the fourth quarter worth about $33,000. 85.07% of the stock is currently owned by institutional investors.

McKesson Stock Down 0.8%

Shares of NYSE:MCK opened at $866.02 on Friday. The stock has a market cap of $106.08 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 1.25 and a beta of 0.42. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The business's 50 day moving average is $916.22 and its 200 day moving average is $851.24.

McKesson (NYSE:MCK - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion for the quarter, compared to analysts' expectations of $105.98 billion. During the same quarter in the previous year, the firm earned $8.03 earnings per share. McKesson's quarterly revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities research analysts expect that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd were paid a $0.82 dividend. The ex-dividend date was Monday, March 2nd. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson's payout ratio is presently 9.43%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on MCK shares. Evercore restated an "outperform" rating on shares of McKesson in a research report on Thursday, March 5th. Barclays raised their price objective on McKesson from $960.00 to $1,050.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Wells Fargo & Company raised their price objective on McKesson from $914.00 to $925.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 5th. Mizuho raised their price objective on McKesson from $880.00 to $885.00 and gave the stock a "neutral" rating in a research report on Thursday, February 5th. Finally, Wall Street Zen downgraded McKesson from a "buy" rating to a "hold" rating in a research report on Saturday. Thirteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, McKesson currently has an average rating of "Moderate Buy" and a consensus target price of $970.93.

Insider Transactions at McKesson

In related news, Director Maria Martinez sold 349 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total transaction of $328,014.63. Following the sale, the director directly owned 301 shares in the company, valued at approximately $282,900.87. The trade was a 53.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Leann B. Smith sold 190 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the sale, the executive vice president owned 2,989 shares in the company, valued at approximately $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 3,592 shares of company stock valued at $3,518,555. Corporate insiders own 0.08% of the company's stock.

McKesson Company Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.